313 related articles for article (PubMed ID: 30626409)
1. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
[TBL] [Abstract][Full Text] [Related]
2. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
[TBL] [Abstract][Full Text] [Related]
3. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
Portella MJ; de Diego-Adeliño J; Ballesteros J; Puigdemont D; Oller S; Santos B; Álvarez E; Artigas F; Pérez V
J Clin Psychiatry; 2011 Jul; 72(7):962-9. PubMed ID: 21034693
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
6. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
[TBL] [Abstract][Full Text] [Related]
8. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
9. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Furey ML; Drevets WC
Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
14. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
Trials; 2011 Jan; 12():4. PubMed ID: 21208417
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
16. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.
Lyoo IK; Yoon S; Kim TS; Hwang J; Kim JE; Won W; Bae S; Renshaw PF
Am J Psychiatry; 2012 Sep; 169(9):937-945. PubMed ID: 22864465
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
